Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer

Hiroyuki Watanabe, Hiroaki Ikesue, Marina Oshiro, Kenichiro Nagata, Kazuto Mishima, Atsushi Takada, Kimitaka Suetsugu, Masanori Sueyasu, Nobuaki Egashira, Taishi Harada, Koichi Takayama, Yoichi Nakanishi, Ryozo Oishi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Neutropenia is one of the most frequent and dose-limiting toxicities in amrubicin (AMR) therapy. However, the predictive factors for the development of severe neutropenia in AMR therapy remain unknown. Methods: The subjects were 61 advanced lung cancer patients treated with AMR monotherapy. All data were retrospectively collected from the electronic medical record system. A stepwise logistic regression analysis was performed to identify risk factors for grade 3-4 neutropenia. Results: Of a total 61 patients, 50 were male and 11 were female. The median dose of AMR was 35.0 mg/m2. The incidence of grade 3-4 neutropenia during the first course was 62%. In multivariate analysis, female gender (OR = 6.68; 95% CI 1.01-134.15; p = 0.049), higher AMR doses (40 mg/m2 or more) (OR = 5.98; 95% CI 1.77-23.74; p = 0.003), and lower hematocrit values (OR = 2.04 per 5% decrease; 95% CI 1.04-4.38; p = 0.036) were significantly associated with severe neutropenia induced by AMR. Conclusion: The present results suggest that female gender, higher doses of AMR, and lower baseline hematocrit values are predictive factors associated with severe neutropenia induced by AMR in patients with advanced lung cancer. Patients who have these predictive factors should be monitored carefully and considered for early granulocyte colony-stimulating factor support.

Original languageEnglish
Pages (from-to)419-425
Number of pages7
JournalCHEMOTHERAPY
Volume58
Issue number6
DOIs
Publication statusPublished - Apr 1 2013

Fingerprint

Neutropenia
Lung Neoplasms
Hematocrit
amrubicin
Electronic Health Records
Granulocyte Colony-Stimulating Factor
Multivariate Analysis
Logistic Models
Regression Analysis
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Watanabe, H., Ikesue, H., Oshiro, M., Nagata, K., Mishima, K., Takada, A., ... Oishi, R. (2013). Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer. CHEMOTHERAPY, 58(6), 419-425. https://doi.org/10.1159/000345617

Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer. / Watanabe, Hiroyuki; Ikesue, Hiroaki; Oshiro, Marina; Nagata, Kenichiro; Mishima, Kazuto; Takada, Atsushi; Suetsugu, Kimitaka; Sueyasu, Masanori; Egashira, Nobuaki; Harada, Taishi; Takayama, Koichi; Nakanishi, Yoichi; Oishi, Ryozo.

In: CHEMOTHERAPY, Vol. 58, No. 6, 01.04.2013, p. 419-425.

Research output: Contribution to journalArticle

Watanabe, H, Ikesue, H, Oshiro, M, Nagata, K, Mishima, K, Takada, A, Suetsugu, K, Sueyasu, M, Egashira, N, Harada, T, Takayama, K, Nakanishi, Y & Oishi, R 2013, 'Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer', CHEMOTHERAPY, vol. 58, no. 6, pp. 419-425. https://doi.org/10.1159/000345617
Watanabe, Hiroyuki ; Ikesue, Hiroaki ; Oshiro, Marina ; Nagata, Kenichiro ; Mishima, Kazuto ; Takada, Atsushi ; Suetsugu, Kimitaka ; Sueyasu, Masanori ; Egashira, Nobuaki ; Harada, Taishi ; Takayama, Koichi ; Nakanishi, Yoichi ; Oishi, Ryozo. / Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer. In: CHEMOTHERAPY. 2013 ; Vol. 58, No. 6. pp. 419-425.
@article{6e0ced26ccf4485aa3ea4b74d0a7857a,
title = "Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer",
abstract = "Background: Neutropenia is one of the most frequent and dose-limiting toxicities in amrubicin (AMR) therapy. However, the predictive factors for the development of severe neutropenia in AMR therapy remain unknown. Methods: The subjects were 61 advanced lung cancer patients treated with AMR monotherapy. All data were retrospectively collected from the electronic medical record system. A stepwise logistic regression analysis was performed to identify risk factors for grade 3-4 neutropenia. Results: Of a total 61 patients, 50 were male and 11 were female. The median dose of AMR was 35.0 mg/m2. The incidence of grade 3-4 neutropenia during the first course was 62{\%}. In multivariate analysis, female gender (OR = 6.68; 95{\%} CI 1.01-134.15; p = 0.049), higher AMR doses (40 mg/m2 or more) (OR = 5.98; 95{\%} CI 1.77-23.74; p = 0.003), and lower hematocrit values (OR = 2.04 per 5{\%} decrease; 95{\%} CI 1.04-4.38; p = 0.036) were significantly associated with severe neutropenia induced by AMR. Conclusion: The present results suggest that female gender, higher doses of AMR, and lower baseline hematocrit values are predictive factors associated with severe neutropenia induced by AMR in patients with advanced lung cancer. Patients who have these predictive factors should be monitored carefully and considered for early granulocyte colony-stimulating factor support.",
author = "Hiroyuki Watanabe and Hiroaki Ikesue and Marina Oshiro and Kenichiro Nagata and Kazuto Mishima and Atsushi Takada and Kimitaka Suetsugu and Masanori Sueyasu and Nobuaki Egashira and Taishi Harada and Koichi Takayama and Yoichi Nakanishi and Ryozo Oishi",
year = "2013",
month = "4",
day = "1",
doi = "10.1159/000345617",
language = "English",
volume = "58",
pages = "419--425",
journal = "Chemotherapy",
issn = "0009-3157",
publisher = "S. Karger AG",
number = "6",

}

TY - JOUR

T1 - Risk factors for predicting severe neutropenia induced by amrubicin in patients with advanced lung cancer

AU - Watanabe, Hiroyuki

AU - Ikesue, Hiroaki

AU - Oshiro, Marina

AU - Nagata, Kenichiro

AU - Mishima, Kazuto

AU - Takada, Atsushi

AU - Suetsugu, Kimitaka

AU - Sueyasu, Masanori

AU - Egashira, Nobuaki

AU - Harada, Taishi

AU - Takayama, Koichi

AU - Nakanishi, Yoichi

AU - Oishi, Ryozo

PY - 2013/4/1

Y1 - 2013/4/1

N2 - Background: Neutropenia is one of the most frequent and dose-limiting toxicities in amrubicin (AMR) therapy. However, the predictive factors for the development of severe neutropenia in AMR therapy remain unknown. Methods: The subjects were 61 advanced lung cancer patients treated with AMR monotherapy. All data were retrospectively collected from the electronic medical record system. A stepwise logistic regression analysis was performed to identify risk factors for grade 3-4 neutropenia. Results: Of a total 61 patients, 50 were male and 11 were female. The median dose of AMR was 35.0 mg/m2. The incidence of grade 3-4 neutropenia during the first course was 62%. In multivariate analysis, female gender (OR = 6.68; 95% CI 1.01-134.15; p = 0.049), higher AMR doses (40 mg/m2 or more) (OR = 5.98; 95% CI 1.77-23.74; p = 0.003), and lower hematocrit values (OR = 2.04 per 5% decrease; 95% CI 1.04-4.38; p = 0.036) were significantly associated with severe neutropenia induced by AMR. Conclusion: The present results suggest that female gender, higher doses of AMR, and lower baseline hematocrit values are predictive factors associated with severe neutropenia induced by AMR in patients with advanced lung cancer. Patients who have these predictive factors should be monitored carefully and considered for early granulocyte colony-stimulating factor support.

AB - Background: Neutropenia is one of the most frequent and dose-limiting toxicities in amrubicin (AMR) therapy. However, the predictive factors for the development of severe neutropenia in AMR therapy remain unknown. Methods: The subjects were 61 advanced lung cancer patients treated with AMR monotherapy. All data were retrospectively collected from the electronic medical record system. A stepwise logistic regression analysis was performed to identify risk factors for grade 3-4 neutropenia. Results: Of a total 61 patients, 50 were male and 11 were female. The median dose of AMR was 35.0 mg/m2. The incidence of grade 3-4 neutropenia during the first course was 62%. In multivariate analysis, female gender (OR = 6.68; 95% CI 1.01-134.15; p = 0.049), higher AMR doses (40 mg/m2 or more) (OR = 5.98; 95% CI 1.77-23.74; p = 0.003), and lower hematocrit values (OR = 2.04 per 5% decrease; 95% CI 1.04-4.38; p = 0.036) were significantly associated with severe neutropenia induced by AMR. Conclusion: The present results suggest that female gender, higher doses of AMR, and lower baseline hematocrit values are predictive factors associated with severe neutropenia induced by AMR in patients with advanced lung cancer. Patients who have these predictive factors should be monitored carefully and considered for early granulocyte colony-stimulating factor support.

UR - http://www.scopus.com/inward/record.url?scp=84871895184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871895184&partnerID=8YFLogxK

U2 - 10.1159/000345617

DO - 10.1159/000345617

M3 - Article

VL - 58

SP - 419

EP - 425

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3157

IS - 6

ER -